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Sir, in osteoarthritic synovial fluid, the molecular weight and
concentration of hyaluronic acid (HA) are decreased due
to dilutional effects, aberrant hyaluronan synthesis, and
free radical degradation. Consequently, the biologic
and mechanical properties normally provided by HA are
compromised in involved joints.
Viscosupplementation (VS) is the administration of hy-
aluronan preparations to the synovial fluid of the joints for
the treatment of osteoarthritis (OA) in order to restore the
biological properties of normal HA1.
Studies have shown that HA injections provide prolonged
relief from symptoms in patients with OA of the knee2. The
mechanisms whereby HA exerts its therapeutic effects in
osteoarthritic joints are not completely understood. How-
ever, there is an increasing evidence to suggest that clinical
efficacy may be mediated through several different path-
ways: restoration of joint rheology, anti-inflammatory effect,
anti-nociceptive effects, normalisation of endogenous HA
synthesis, and chondroprotection.
There are many studies regarding VS in OA of the
knee3,4, but there is little available data regarding VS in OA
of the hip. The knee joint is relatively easy to inject; on the
contrary, it may be dangerous to infiltrate the hip owing to
the uncertainty of injecting into the joint cavity. To resolve
this problem, we propose an ultrasound-guided intra-
articular (IA) injection technique. In this way, we are able to
extend the same benefits as achieved by VS in OA of the
knee to OA of the hip.
We enrolled 28 patients affected by mono or bilateral OA
of the hip according to the ARA criteria. All patients
had radiographic changes of OA equal to Kellgren and
Lawrence grades II, III, and IV. Demographic features were:
nine males, 19 females, mean age, 66 (range 55–78). Each
patient was treated with one to three injections of hyaluro-
nan preparations with molecular weight of 0.5–0.75 or 1.0
million every 15 days for a total of 78 injections. Exclusion
criteria were concomitant anticoagulant therapy. All the
patients were examined supine with the hip in internal-
rotatore of 15–20°. A 7 MHz linear or 3.5 MHz convex
transducer (ASTRO 256, Hitachi-Esaote, Genova, Italy)
were used with a sterilised biopsy guide attached. Hip joint
was scanned by means of an anterior parasagittal ap-
proach, lateral to the femoral vessels. The transducer was
aligned with the long axis of the femoral neck, compending
also the acetabulum and the femoral head. IA injection was
administered by inserting into the biopsy guide a 20 gauge
(9 cm) spinal needle with the anterosuperior approach.
Then, using a biopsy real time guidance software, the
needle was advanced into the anterior capsular recess, at
the level of the femoral head. Once the needle came into
contact with the femoral head, the needle was retracted by
1 mm. Then, the hyaluronan preparation was injected into
the hip joint and verification of IA placement was evident
with the real-time monitoring (direct visualisation of viscous
fluid or air bubbles) also utilising power Doppler imaging
(flow signals in IA recess) (Figs. 1 and 2). The colour
Doppler vision allowed us to avoid injecting blood vessels.
Lequesne-index (LE) was determined to evaluate treat-
ment efficacy. Pain relief was evaluated by a visual ana-
logue scale (VAS). The NSAID administration was also
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Fig. 1. The ultrasound probe with biopsy guide is placed in a
parasagittal plane over the hip. The needle is inserted antero-
superiorly into the joint.
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evaluated. Student’s t tests were performed to compare LE
and VAS before and after treatment. NSAID intake was
also compared.
LE media score were 73.2±16.95 SD before treatment
and 56.25±20.4 SD after treatment. Student’s t test showed
P<0.001. VAS media score pain were 8.63±1.6 SD before
treatment and 6.23±2.4 SD after treatment. Student’s t test
showed P<0.001. The comparison of the monthly NSAID
intake before and after treatment showed a decrease by
48%.
No patient judged their condition as worsening or
unchanged. No systemic side effects were observed. No
infectious complications were reported. Four patients re-
ported a sensation of heaviness and pain in his hip for two
to five days after the IA injection, but they did not require
any medication or need to suspend daily activity. Another
patient reported a transient haematoma of superficial tissue
at the site of IA injection. No other adverse local effects
were observed.
These preliminary data suggest that our technique of VS
of the hip is an easy, safe, and secure way to administer HA
into the joint cavity.
Ultrasound-guided IA injection of HA in the hip is well
tolerated, the few adverse events were local and resolved
spontaneously in a few days. Ultrasound guidance is harm-
less and economic, while, on the contrary, radiological
guidance implies a radiation load and is more expensive.
VS may be associated with NSAID therapy or performed as
a unique treatment in patients who cannot receive NSAIDs.
Patients affected by localised OA of the hip are mainly
susceptible to the ultrasound-guided VS. This treatment
may be helpful to patients waiting for joint replacement,
because it improves their quality of life. There is also a
reduction of direct and indirect healthcare costs in relation
to decreased NSAID’s intake.
Duration of the clinical benefit after treatment will be
evaluated through the follow-up of these patients.
We hope to transfer to OA of the hip, the same benefits
produced by VS in OA of the knee.
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Fig. 2. Longitudinal ultrasonographic scan of the hip joint. The
anterior surfaces of the acetabulum along with the head and the
neck of the femoral bone are noted. The capsule is depicted as
the anterior hyperechoic layer following the profile of the femoral
bone. The needle is indicated by the arrows.
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